Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (141-150 of 244) with videos related to

Pageof 25
Sort By:
Blood|November 19, 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaMonica S Nair, Sara K Silbert, Kai Rejeski, et al.
Leukemia|November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadeMichael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
American Journal of Hematology|September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panelFarhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Oncoimmunology|September 20, 2018
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsTodd A Braciak, Claudia C Roskopf, Sarah Wildenhain, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Journal of Hematology & Oncology|January 17, 2025
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adultsMaike Breidenbach, Peter Bader, Andishe Attarbaschi, et al.
Haematologica|February 15, 2024
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adultsTobias Feuchtinger, Peter Bader, Marion Subklewe, et al.
Pageof 25

Showing results (141-150 of 244) with videos related to

Sort By:
Pageof 25
Blood|November 19, 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaMonica S Nair, Sara K Silbert, Kai Rejeski, et al.
Leukemia|November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadeMichael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
American Journal of Hematology|September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panelFarhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Oncoimmunology|September 20, 2018
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsTodd A Braciak, Claudia C Roskopf, Sarah Wildenhain, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Journal of Hematology & Oncology|January 17, 2025
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adultsMaike Breidenbach, Peter Bader, Andishe Attarbaschi, et al.
Haematologica|February 15, 2024
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adultsTobias Feuchtinger, Peter Bader, Marion Subklewe, et al.
Pageof 25